Alkermes Plc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 20, 2026, specifically the Company's 2026 Annual General Meeting of Shareholders. Alkermes Plc. is incorporated in Ireland and its ordinary shares trade on the Nasdaq Global Select Market under the symbol ALKS.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Corporate Actions
The following material actions were approved by shareholders at the Annual Meeting:
- Equity Plan Amendment: Shareholders approved an amendment to the 2018 Stock Option and Incentive Plan, increasing the number of ordinary shares authorized for issuance by 5,900,000.
- Board Elections: Nine directors were elected to one-year terms. All nominees received majority support, though vote counts varied by candidate.
- Executive Compensation: Shareholders approved the advisory "say-on-pay" vote for named executive officers.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent auditor.
- Share Issuance Authority: The Board was granted renewed authority to allot and issue shares and to disapply statutory pre-emption rights under Irish law.
Voting Results Summary
| Proposal | Votes For | Votes Against | Abstain |
|---|---|---|---|
| Election of Directors (Aggregate) | 1,247,654,026 | 35,741,780 | 1,448,838 |
| Executive Compensation (Say-on-Pay) | 139,234,176 | 1,787,311 | 148,488 |
| Auditor Ratification | 146,222,286 | 2,812,663 | 46,653 |
| 2018 Plan Amendment | 128,147,910 | 12,952,836 | 69,229 |
| Share Allotment Authority | 148,661,934 | 382,138 | 37,531 |
| Disapplication of Pre-emption Rights | 146,903,611 | 2,086,009 | 91,983 |
Note: Broker non-votes totaled 7,911,628 for director elections and the equity plan amendment.
Outlook, Risks, and Contingencies
This filing does not contain management commentary on future outlook, specific risks, or contingencies. It strictly reports the outcomes of shareholder votes and the amendment of the equity incentive plan.
Investor Verification Checklist
- Verify the impact of the 5,900,000 share increase on potential dilution by reviewing the full text of the amended 2018 Plan (Exhibit 10.1).
- Review the definitive proxy statement filed on April 6, 2026, for detailed biographies of the newly elected directors and the rationale for the equity plan amendment.
- Monitor subsequent filings (10-K or 10-Q) for actual financial performance, as this 8-K contains no financial data.
- Confirm the effective date of the renewed share issuance authority to understand the timeline for potential capital raises.